IR情報

2020/07/16~2020/12/14

IR情報&株価推移

日付始値高値安値終値前日比出来高時価総額25日乖離
2020
12/147,5687,6607,5677,650+0.38%705,4002兆2687億-1.3%
12/117,6537,7307,5217,621-1.05%1,314,4002兆2601億-2.97%
12/1012:30 アデュカヌマブ、日本において新薬承認を申請
12/107,4927,8417,4527,702+2.07%2,116,3002兆2841億-3.06%
12/097,4827,5777,4817,546+0.88%1,351,7002兆2378億-5.34%
12/087,5987,5987,4767,480-1.77%1,272,5002兆2183億-6.46%
12/077,7257,7407,5737,615-0.81%819,2002兆2583億-5.06%
12/047,6907,7027,6477,677-0.17%621,4002兆2767億-4.65%
12/037,7497,7497,6317,690-1.21%1,000,0002兆2805億-4.85%
12/027,8487,8647,7717,784-0.42%887,7002兆3084億-4.04%
12/017,8887,9827,8017,817-0.89%916,3002兆3182億-3.96%
11/307,8627,9027,7357,887+1.34%2,049,2002兆3390億-3.33%
11/277,8167,8277,7467,783-0.46%1,096,6002兆3081億-4.83%
11/267,7907,8257,7457,819+1.16%732,4002兆3188億-4.76%
11/257,8477,8767,7217,729-0.78%969,5002兆2921億-6.22%
11/247,8187,8407,7527,790+0.62%890,5002兆3102億-5.93%
11/207,7977,7977,7187,742-0.72%670,1002兆2960億-6.85%
11/197,6997,7987,6377,798+1.29%1,102,8002兆3126億-6.64%
11/187,7477,7867,6447,699-0.16%992,9002兆2832億-8.33%
11/177,8007,8077,6847,711-1.31%1,296,1002兆2868億-8.76%
11/167,9807,9867,8117,813-2.13%1,457,6002兆3170億-8.24%
11/138,0008,0427,9117,983-0.09%1,158,8002兆3674億-6.93%
11/128,0108,0607,9197,990+1.06%1,383,3002兆3695億-7.54%
11/117,7667,9447,7377,906+2.41%1,929,4002兆3446億-9.14%
11/107,8877,8997,6607,720-1.27%2,813,4002兆2894億-12.02%
11/097,7707,9177,5587,819-23.64%5,154,9002兆3188億-11.69%
11/0710:15 アルツハイマー病におけるアデュカヌマブに関するFDA諮問委員会について
11/0610,54010,90010,20010,240+3.7%4,587,2003兆368億+14.76%
11/0515:30 2020年度第2四半期決算説明会資料
11/0512:30 2021年3月期第2四半期決算短信参考資料[IFRS]
11/0512:30 2021年3月期第2四半期決算短信[IFRS](連結)
11/059,8759,8759,8759,875+17.91%186,1002兆9285億+10.99%
11/048,3308,4428,1948,375+2.38%782,5002兆4837億-5.74%
11/028,0708,2208,0708,180+1.12%633,9002兆4259億-8.46%
10/3020:00 アデュカヌマブ、アルツハイマー病治療薬として、欧州医薬品庁への販売承認申請が受理
10/308,3078,3798,0768,089-3.3%1,124,3002兆3989億-10.01%
10/298,3458,4688,3458,365-0.82%439,1002兆4807億-7.5%
10/288,4408,4888,3938,434-0.28%488,0002兆5012億-7.22%
10/278,3848,4708,3288,458+0.08%441,5002兆5083億-7.42%
10/268,4398,4948,3908,451+1.45%449,1002兆5062億-7.91%
10/238,3488,3878,2808,330-0.3%494,6002兆4704億-9.61%
10/228,5598,5598,3428,355-2.51%521,4002兆4778億-9.73%
10/2120:30 アデュカヌマブの欧州医薬品庁への販売承認申請の提出について
10/218,5908,6038,5188,570-0.79%452,5002兆5415億-7.78%
10/208,5908,6778,5468,638-0.64%595,3002兆5617億-7.33%
10/198,5908,6988,5668,694+1.66%687,4002兆5783億-6.97%
10/168,7128,7558,5368,552-2.69%728,1002兆5362億-8.69%
10/158,8758,9048,7318,788-1.71%727,4002兆6062億-6.46%
10/148,9538,9808,8908,941-0.62%652,6002兆6516億-5.07%
10/139,2679,2828,9538,997-3.29%1,013,5002兆6682億-4.67%
10/129,3509,4009,2399,303-0.77%548,3002兆7589億-1.66%
10/099,5919,5929,3289,375-2.49%1,029,4002兆7803億-0.97%
10/089,5349,6689,4829,614+1.74%596,8002兆8511億+1.52%
10/079,6339,6809,4169,450-3.2%790,3002兆8025億-0.06%
10/069,6869,8249,6839,762+0.71%455,0002兆8950億+3.38%
10/059,6459,7809,6009,693+1.57%658,4002兆8746億+2.8%
10/029,6459,6759,4909,543-0.43%617,8002兆8301億+1.33%
09/309,6259,6919,5519,584+0.13%929,3002兆8422億+1.83%
09/299,6319,6749,4339,572-0.83%542,4002兆8387億+1.79%
09/289,5999,6609,5189,652+1.37%692,9002兆8624億+2.77%
09/259,4659,5779,4659,522+0.96%582,1002兆8239億+1.5%
09/249,5239,5409,3839,431-1.23%552,6002兆7969億+0.58%
09/239,5429,5979,4899,548-0.2%662,4002兆8316億+1.83%
09/189,5009,5829,4419,567+0.78%777,4002兆8372億+2%
09/179,3719,4939,3479,493+0.61%436,4002兆8153億+1.17%
09/169,3179,4479,2959,435+1.17%511,7002兆7981億+0.59%
09/159,3109,3329,2529,326+0.63%410,5002兆7657億-0.51%
09/149,2429,2959,2299,268-0.13%399,7002兆7485億-1.34%
09/119,3369,3369,0659,280+0.53%1,098,9002兆7521億-0.94%
09/109,2949,3179,1819,231+0.2%588,8002兆7376億-1.15%
09/099,2139,2949,1329,213-0.7%658,3002兆7322億-1.1%
09/089,3759,4589,2009,278-1.35%713,9002兆7515億-0.2%
09/079,5009,5569,4039,405-0.14%438,5002兆7892億+1.38%
09/049,3999,4879,3819,418-1.37%537,0002兆7930億+1.93%
09/039,5279,5879,4849,549+0.77%575,0002兆8319億+3.62%
09/029,3659,5009,3409,476+0.42%546,2002兆8102億+3.17%
09/019,4159,5119,3769,436+1.85%693,0002兆7984億+3.05%
08/319,2909,3429,1819,265+1.37%723,6002兆7476億+1.49%
08/289,3009,3388,8889,140-2.75%844,1002兆7106億+0.34%
08/279,4019,4169,3509,398-0.12%296,9002兆7871億+3.34%
08/269,4129,4529,3729,409-0.05%331,1002兆7903億+3.85%
08/259,4409,5039,3659,414+0.41%555,3002兆7918億+4.32%
08/249,2929,3859,2769,376+1.06%408,1002兆7806億+4.4%
08/219,3649,3969,2669,278-0.87%712,0002兆7515億+3.73%
08/209,3159,4249,2959,359-0.75%616,6002兆7755億+4.95%
08/199,3709,4859,3569,430+0.14%792,1002兆7966億+6.09%
08/189,6209,6279,4179,417-2.02%962,6002兆7927億+6.27%
08/179,6109,6389,5599,611-0.62%629,3002兆8503億+8.7%
08/149,5429,7079,4619,671+2.74%1,062,5002兆8680億+9.91%
08/139,4989,5289,3109,413+1.3%1,021,1002兆7915億+7.55%
08/129,7009,7629,1889,292-5.29%1,544,6002兆7557億+6.56%
08/119,2269,8909,2239,811+13.74%2,951,2002兆9096億+12.91%
08/0720:30 アデュカヌマブ、アルツハイマー病治療薬としてのBLA申請が米国FDAに受理され、優先審査に指定
08/078,6888,6908,5378,626+1.03%578,4002兆5581億-0.09%
08/068,6288,6678,4898,538-1.44%523,6002兆5320億-1.07%
08/058,7608,7608,5508,663-1.01%568,2002兆5691億+0.37%
08/048,8008,9708,7338,751-0.3%629,5002兆5952億+1.45%
08/0315:30 2020年度第1四半期決算説明会資料
08/0312:30 2021年3月期第1四半期決算短信参考資料〔IFRS〕
08/0312:30 2021年3月期第1四半期決算短信〔IFRS〕(連結)
08/038,6378,8398,5058,777+3.42%889,3002兆6029億+1.75%
07/318,7108,7468,4728,487-3.38%628,7002兆5169億-1.54%
07/308,7508,8128,6808,784-0.13%359,2002兆6050億+1.82%
07/298,7858,8638,7768,795+0.11%327,4002兆6083億+2.03%
07/288,8408,8718,7538,785+0.45%443,9002兆6053億+2.04%
07/278,6368,8158,6308,746+0.05%615,0002兆5937億+1.73%
07/228,6678,7758,6408,742-0.29%462,9002兆5925億+1.77%
07/218,6088,8158,6088,767+2.54%642,9002兆6000億+2.14%
07/208,4758,5728,4548,550+0.48%372,1002兆5356億-0.35%
07/178,4898,6188,4418,509+1.97%912,9002兆5234億-0.64%
07/168,4478,5048,3128,345-1.37%947,3002兆4748億-2.5%